对Helicobacter pylori根除的高剂量双重治疗诱导对肠道微生物群的影响较小
Jia-Lun Guan1, Ting-Ting Xu2, Ya Lin2
1Division of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, China.
Gut pathogens
|January 30, 2025
概括
针对H. pylori根除的高剂量双疗法 (HDDT) 对肠道微生物群的多样性和组成的影响较低,而比斯木斯四重疗法 (BQT) 影响更小. 对于患者来说,HDDT提供了一个潜在的更安全的微生态选择.
科学领域:
- 微生物学 微生物学
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 杆菌根除方案可以影响肠道微生物群.
- 关于高剂量双重治疗 (HDDT) 的微生态安全性研究有限.
- 这项研究比较了HDDT和 bismuth四重疗法 (BQT) 对肠道微生物群的影响.
研究的目的:
- 为了比较HDDT和BQT对肠道微生物群多样性和组成的影响.
- 评估HDDT在H.pylori根除中的微生态安全性.
主要方法:
- 招募了H. pylori感染的,未接受过治疗的患者.
- 随机分配的患者在14天内接受HDDT或BQT.
- 使用16S rRNA基因测序分析了治疗前收集的便样本上的肠道微生物群,并在治疗后的第2周和第8周收集了便样本.
主要成果:
- 在第二周,BQT显著改变了肠道微生物群的多样性,在第八周不完全恢复.
- 在第2周,HDDT仅显示了肠道微生物群多样性的轻微,无意义的变化.
- 两种疗法都在第8周恢复了物种丰度,但BQT最初造成了更多的改变.
结论:
- 与BQT相比,HDDT对肠道微生物群的多样性和组成的影响较小.
- 关于肠道微生态平衡的H. pylori根除,HDDT可能是一个更安全的替代方案.
相关概念视频
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
320
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
320
Peptic Ulcer Disease IV: Management
60
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
60
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
80
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
80
Gastritis III: Clinical Manifestations and Management
129
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
129
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
350
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
350
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
347
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
347


